COPD Exacerbation, PTE - Pulmonary Thromboembolism
Conditions
Brief summary
Anticoagulation is the most important treatment for pulmonary thromboembolism (PTE). The thromboembolism risk is especially high in patients with chronic obstructive pulmonary disease (COPD) exacerbations. However, there's no agreement on the most appropriate duration of anticoagulation in COPD with PTE to balance the risk of recurrence of thrombosis and bleeding. This randomized, controlled trial aims to evaluate the risk and benefit of prolonged anticoagulation compared with the regular 3-month anticoagulation in COPD with PTE.
Interventions
DRUGWarfarin
tailored dose according to international normalized ratio (INR) for 3 months
Sponsors
Chinese Academy of Medical Sciences, Fuwai Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Hospitalized patients due to chronic obstructive pulmonary disease exacerbation and diagnosed as newly developed pulmonary thromboembolism * Regular anticoagulation for 3 months and got CT pulmonary angiography
Exclusion criteria
* Patients with major bleeding during prior anticoagulation * Patients need long term anticoagulation to treat other diseases * Patients unwilling to receive prolonged anticoagulation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Venous thromboembolism recurrence | 3 years | recurrence rate in % |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Chronic obstructive pulmonary disease exacerbations | 3 year | total times |
Countries
China
Contacts
Primary ContactYuanhua Yang, MD
Outcome results
None listed